Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Betamethasone Dipropionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 7/20 | 0.91 |
| ▸ | PGR | P06401 | 5/20 | 0.91 |
| ▸ | MAPT | P10636 | 3/20 | 0.91 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.91 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.91 |
| ▸ | DRD2 | P14416 | 1/20 | 0.91 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.91 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.77 |
| ▸ | USP2 | O75604 | 5/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | MLNR | O43193 | 1/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.77 |
| ▸ | PPARG | P37231 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.74 |
| ▸ | AR | P10275 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betamethasone Dipropionate SCHEMBL8419 | 1.00 | NR3C1 (0.91) | NR3C1PGRMAPTNR1I2ADORA3 | |
| Betamethasone Dipropionate SCHEMBL16213556 | 1.00 | NR3C1 (0.91) | NR3C1PGRMAPTNR1I2ADORA3 | |
| Betamethasone Dipropionate SCHEMBL1658520 | 0.98 | NR3C1 (0.88) | NR3C1PGRMAPTNR1I2ADORA3 | |
| Betamethasone Dipropionate SCHEMBL8584606 | 0.98 | NR3C1 (0.90) | NR3C1PGRMAPTNR1I2ADORA3 | |
| Betamethasone Dipropionate SCHEMBL2271231 | 0.98 | NR3C1 (0.90) | NR3C1PGRMAPTNR1I2ADORA3 | |
| Betamethasone Dipropionate SCHEMBL3836657 | 0.98 | NR3C1 (0.90) | NR3C1PGRMAPTNR1I2ADORA3 | |
| Betamethasone Dipropionate SCHEMBL11064031 | 0.96 | NR3C1 (0.86) | NR3C1PGRMAPTNR1I2ADORA3 | |
| Betamethasone Dipropionate SCHEMBL9768468 | 0.96 | NR3C1 (1.00) | NR3C1PGRMAPTNR1I2ADORA3 | |
| Betamethasone Dipropionate SCHEMBL11429865 | 0.96 | NR3C1 (1.00) | NR3C1PGRMAPTNR1I2ADORA3 | |
| Betamethasone Dipropionate SCHEMBL10013893 | 0.96 | NR3C1 (1.00) | NR3C1PGRMAPTNR1I2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114901277-B | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-116783180-A | Tricyclic ligands for degradation of IKZF2 or IKZF4 | C4医药公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116615210-A | Novel anuclear cells as a source for the treatment of platelet-rich plasma-dependent disorders | 血小板生源说股份有限公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-116390951-A | PD-L1 binding agents and uses thereof | 埃克塞里艾克西斯公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-115772167-A | Compound containing urea structure and application thereof | 暨南大学 | 2023-03-10 | — | — | CN | disclosed |
| CN-115698717-A | Methods of treatment and diagnosis of cancer | 基因泰克公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-112313213-B | 3-amino pyrazole compound and application thereof | 上海海和药物研究开发股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-107207493-B | Substituted pyrrolopyridines as bromodomain inhibitors | 基因泰克公司 | 2023-01-20 | — | — | CN | disclosed |
| CN-110437220-B | Triazole compound and application thereof | 暨南大学 | 2022-12-27 | — | — | CN | disclosed |
| CN-115477611-A | MRGPRX2 antagonists for the treatment of pseudoallergy | 香港大学 | 2022-12-16 | — | — | CN | disclosed |
| US-6214378-B1 | USEFUL FOR THERAPY OF COLON CANCER, ULCERATIVE COLITIS, CONSTIPATION, DIARRHEA, OSTEOPOROSIS; CAPSULE DOES NOT UNDERGO CHANGE IN STOMACH AND IN SMALL INTESTINE BUT STARTS DISINTEGRATION IN LARGE INTESTINE | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2001-04-10 | — | — | US | disclosed |
| EP-0622072-B1 | Stable aqueous dispersions containing liposomes | WAKAMOTO PHARMA CO LTD (JP) | 2000-09-06 | — | — | EP | disclosed |
| EP-0953357-A1 | NEPHROTROPIC DRUGS | Drug Delivery System Institute, Ltd. (JP) | 1999-11-03 | — | — | EP | disclosed |
| EP-0919228-A1 | CAPSULES FOR ORAL PREPARATIONS AND CAPSULE PREPARATIONS FOR ORAL ADMINISTRATION | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1999-06-02 | — | — | EP | disclosed |
| US-5710148-A | FUMAGILLOL DERIVATIVES | SENJU PHARMACEUTICALS CO., LTD. (JP) | 1998-01-20 | — | — | US | disclosed |
| EP-0780129-A2 | Adrenal cortical steroid containing external therapeutic composition for dermatitis | CAC Corporation (JP) | 1997-06-25 | — | — | EP | disclosed |
| US-5569464-A | ENCAPSULATING DRUGS | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 1996-10-29 | — | — | US | disclosed |
| EP-0730863-A2 | A corneal opacification inhibitory composition comprising a fumagillol derivative | Senju Pharmaceutical Co., Ltd. (JP) | 1996-09-11 | — | — | EP | disclosed |
| US-5506241-A | INHIBITS FIBRIN FORMATION IN ANTERIOR CHAMBER | MITSUBISHI CHEMICAL CORPORATION (JP) | 1996-04-09 | — | — | US | disclosed |
| EP-0622072-A2 | Stable aqueous dispersions containing liposomes | Wakamoto Pharmaceutical Co., Ltd. (JP) | 1994-11-02 | — | — | EP | disclosed |